Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05727072 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3848575 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT05727072 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 64 participants.
The verdict
NCT05727072, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3848575 when administered either intravenously or subcutaneously in single ascending or multiple doses in healthy non-Japanese and first generation Japanese participants. The study will also assess how fast LY3848575 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 142 days excluding the screening period of 28 days.
Interventions
- DRUG Placebo
- DRUG LY3848575
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-02-10 |
| Est. Completion | 2024-02-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05727072
The ClinicalTrials.gov registry entry for NCT05727072 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05727072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05727072 about?
NCT05727072 is a clinical study titled "A Study of LY3848575 in Healthy Participants". The main purpose of this study is to evaluate the safety and tolerability of LY3848575 when administered either intravenously or subcutaneously in single ascending or multiple doses in healthy non-Japanese and first generation Japanese participants. The study will also assess how fast LY3848575 gets...
What is the current status of trial NCT05727072?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2023-02-10. Estimated completion is 2024-02-19.
What interventions are being tested in trial NCT05727072?
The interventions under investigation include: Placebo (DRUG), LY3848575 (DRUG).
Who is sponsoring clinical trial NCT05727072?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.